{
  "ticker": "JNJ",
  "target_date": "2025-07-22",
  "actual_date": "2025-07-22",
  "collected_at": "2025-12-08T12:02:36.733884",
  "price": {
    "open": 162.76,
    "high": 165.78,
    "low": 162.48,
    "close": 165.6545867919922,
    "volume": 9288000,
    "change_1d_pct": 2.17,
    "change_7d_pct": 7.03,
    "change_30d_pct": 8.32
  },
  "technicals": {
    "rsi_14": 76.28,
    "sma_20": 155.21,
    "sma_50": 152.46,
    "macd": 2.918,
    "macd_signal": 1.767,
    "macd_histogram": 1.151,
    "bb_upper": 164.65,
    "bb_lower": 145.77,
    "price_vs_sma20_pct": 6.73,
    "price_vs_sma50_pct": 8.65,
    "volume_ratio": 1.07
  },
  "fundamentals": {
    "market_cap": 489183248384,
    "pe_ratio": 19.598455,
    "forward_pe": 19.154716,
    "price_to_book": 6.162625,
    "price_to_sales": 5.308612,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.3,
    "pct_from_52w_low": 44.33
  },
  "macro": {
    "spy": {
      "price": 627.12,
      "change_1d_pct": 0.01,
      "change_7d_pct": 0.65
    },
    "vix": {
      "level": 16.5,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.34
    },
    "dollar_index": {
      "level": 97.39
    },
    "gold": {
      "price": 3439.2
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra",
      "source": "Yahoo",
      "datetime": 1753199460,
      "summary": "Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.",
      "url": "https://finnhub.io/api/news?id=46ee6b6845a8e85450cb3219d3a28ad1500ca2381313b6df1dc338009ba8806b"
    },
    {
      "headline": "AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures",
      "source": "Yahoo",
      "datetime": 1753198980,
      "summary": "AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.",
      "url": "https://finnhub.io/api/news?id=2e741b154497c11aacd7734185112b38fb2b6547954a7fd022900bb864a4e989"
    },
    {
      "headline": "Johnson & Johnson Stock Could Be Waking Up",
      "source": "SeekingAlpha",
      "datetime": 1753197118,
      "summary": "Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish technical momentum. Learn more on JNJ stock here.",
      "url": "https://finnhub.io/api/news?id=f2ad56709b94b81c370098ebfe197a9a49480cada5a5cf287ca5f90d7d3b2d97"
    },
    {
      "headline": "How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?",
      "source": "Yahoo",
      "datetime": 1753191060,
      "summary": "ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.",
      "url": "https://finnhub.io/api/news?id=575871e6183099e7c5c71408470fcd8398c2d2ef95611b986cab10f4aa861e38"
    },
    {
      "headline": "Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?",
      "source": "Yahoo",
      "datetime": 1753189204,
      "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=891f53950af149af5c1056a7468f4c94ee8ba62cded00f87a2503783c92b9878"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "13F-HR",
      "date": "2025-07-22",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000367/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-07-18",
      "description": "xslF345X05/wk-form4_1752869553.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000172/xslF345X05/wk-form4_1752869553.xml"
    },
    {
      "form": "8-K",
      "date": "2025-07-16",
      "description": "jnj-20250716.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/jnj-20250716.htm"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760336.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000156/xslF345X05/wk-form4_1749760336.xml"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760229.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000154/xslF345X05/wk-form4_1749760229.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}